Skip to main content
. 2017 Nov 10;25(2):406–420. doi: 10.1038/cdd.2017.176

Figure 8.

Figure 8

Schematic model of miR-20a in regulating drug response. MiR-20a increases drug sensitivity in breast cancer cells through reducing drug efflux by inhibiting P-gp in a MAPK1-dependent manner. In drug-resistant cells, the dysregulated histone methylation inhibits the expression of miR-20a. In addition, miR-20a decreased the expression of c-Myc by inhibiting the MAPK/ERK pathway and formed a feedback loop, thus controlling the drug response and growth signal of the cells